Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets

Table 3

Expression of two microRNAs by real-time PCR validated.

microRNA
	Control group/AS group (fold)	value	AS group before/after therapy (fold)	value
hsa-miR-29a	16.22 (16.22)	0.002	0.31 (3.18)	0.049
hsa-miR-126-3p	3.76 (3.76)	0.046	0.45 (2.20)	0.035

The expression levels of these 2 microRNAs were significantly lower in AS group than in control group. And expressions of them were dramatically upregulated after 12-week etanercept treatment (fold changes >2, < 0.05).